Recro Pharma (REPH) Reports Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive Surgery Global Open Journal
Tweet Send to a Friend
Recro Pharma, Inc. (NASDAQ: REPH), today announced the publication of previously reported Phase III clinical data for intravenous (IV) meloxicam ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
